Morbility and mortality in 229 elderly patients with nonrheumatic atrial fibrillation. A five-year follow-up

Italian Heart Journal

Volumn 4, Issue 8, 2003, Pages 537-543

  Bordin, Paolo ^a,c   Mazzone, Carmine ^b   Pandullo, Claudio ^b   Goldstein, Daniela ^b   Scardi, Sabino ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b Blood Transfusion Center   (Italy)

^c NONE   (Italy)

Author keywords

Anticoagulants; Atrial fibrillation; Embolism; Mortality

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; ITALY; MALE; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RHEUMATIC DISEASE; RISK FACTOR; SEX RATIO; SMOKING; STATISTICS;

AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; ITALY; MALE; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RHEUMATIC DISEASES; RISK FACTORS; SEX DISTRIBUTION; SMOKING;

EID: 1542785379     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-12.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
3. Levy S. Epidemiology and classification of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9 (Suppl): S78-S82.
4. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-78.
5. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51: 674-81.
6. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-8.
7. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112-20.
8. Koudstaal PJ, Koudstaal A. Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. J Thromb Thrombolysis 1999; 7: 61-5.
9. Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
10. Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998; 158: 2093-100.
11. Ang SY, Peterson GM, Friesen WT, Vial JH. Review of antithrombotic drug usage in atrial fibrillation. J Clin Pharm Ther 1998; 23: 97-106.
12. Scardi S, Mazzone C, Pandullo C, et al. A longitudinal study on left atrial thrombosis in patients with non-rheumatic atrial fibrillation treated with anticoagulants. G Ital Cardiol 1997; 27: 1036-43.
13. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108 (Suppl): 352S-359S.
14. Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-Dimensional Echocardiography. Circulation 1990; 62: 212-7.
15. Mügge A, Kühn H, Nikutta P, et al. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607.
16. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.
17. Jung F, DiMarco JP. Treatment strategies for atrial fibrillation. Am J Med 1998; 104: 272-86.
18. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
19. Bharati S, Lev M. Histology of the normal and diseased atrium. In: Falk RH, Podrid PJ, eds. Atrial fibrillation. New York, NY: Raven Press, 1992: 15-40.
20. Rusznak M, Hadhazy C, Szucs M, et al. Incidence of septal aneurysm and its clinical significance. Orv Hetil 1998; 139: 681-4.
21. Brown J, Sadler DB. Left atrial thrombi in non-rheumatic atrial fibrillation: assessment of prevalence by transesophageal echocardiography. Int J Card Imaging 1993; 9: 65-72.
22. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31: 1622-6.
23. Scardi S, Mazzone C, Goldstein D, et al. SFAAT: studio della fibrillazione atriale cronica non reumatica nell'area triestina. Risultati dell'arruolamento. G Ital Cardiol 1995; 25: 173-82.
24. Perez I, Melbourn A, Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999; 82: 570-4.
25. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-34.
26. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in patients ≥ 62 years of age with chronic atrial fibrillation. Am J Cardiol 1998; 82: 119-21.
27. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23: 961-9.
28. The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996; 334: 1216-21.
29. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
30. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-45.
31. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29: 1827-32.
32. Darius H. New developments in anticoagulation therapy in lone atrial fibrillation. Hamostaseologie 2002; 22: 30-5.
33. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.